TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00803582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Description: Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
Study: NCT01450670

Intervention type: DIETARY_SUPPLEMENT
Intervention: Kibow Biotics
Description: Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
Study: NCT04551612

Intervention type: RADIATION
Intervention: Multislice computed tomography temporal bone
Description: Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
Study: NCT04301401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal swabs
Description: On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool samples
Description: Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine samples
Description: Urine samples will also be taken before surgery and 6 weeks after surgery.
Study: NCT03479619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device A
Description: Glucoject Dual Plus lancing device
Study: NCT02219815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehab Intervention
Description: Pre-operative, structured exercise intervention.
Study: NCT03479619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device A
Description: Glucoject Dual Plus lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device A
Description: Glucoject Dual Plus lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device A
Description: Glucoject Dual Plus lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device A
Description: Glucoject Dual Plus lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device A
Description: Glucoject Dual Plus lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device B
Description: Droplet lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device B
Description: Droplet lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device B
Description: Droplet lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device B
Description: Droplet lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device B
Description: Droplet lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device B
Description: Droplet lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device C
Description: Commercially available lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device C
Description: Commercially available lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device C
Description: Commercially available lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device C
Description: Commercially available lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device C
Description: Commercially available lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device C
Description: Commercially available lancing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 G lancet
Description: Droplet 28 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 G lancet
Description: Droplet 28 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 G lancet
Description: Droplet 28 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 G lancet
Description: Droplet 28 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 G lancet
Description: Droplet 28 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 G lancet
Description: Droplet 28 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 G lancet
Description: Droplet personal lancet 30 G
Study: NCT03064646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organ Preservation
Description: Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
Study: NCT02564133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: A transthoracic echocardiography is performed to discover a patent foramen ovale
Study: NCT00834665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT vaccine, GM-CSF, PCV, T cell infusion
Description: hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF, PCV, T cell infusion
Description: Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
Study: NCT02148523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison to peers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence feedback

Intervention type: DEVICE
Group type: OTHER
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Study: NCT04341714

Intervention type: OTHER
Intervention: Satisfaction evaluation
Description: Assessement of satisfaction of the telephone consultation
Study: NCT03059381

Intervention type: DRUG
Intervention: Fycompa
Description: The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
Study: NCT04147338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.
Study: NCT03479619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 G lancet
Description: Droplet personal lancet 30 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 G lancet
Description: Droplet personal lancet 30 G
Study: NCT04147338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.
Study: NCT01457872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength-based case management
Description: Strength-based case management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition - referral only
Description: Referral only
Study: NCT05549193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises Training
Description: Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg.
Study: NCT02398552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
Study: NCT02787252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant procedure, Freedom Spinal Cord Stimulation System
Description: A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
Study: NCT04266808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An interactive telehealth monitoring and biofeedback system
Description: A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
Study: NCT02285231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginyl-fructose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03479619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 G lancet
Description: Droplet personal lancet 30 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 G lancet
Description: Droplet personal lancet 30 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 G lancet
Description: Droplet personal lancet 30 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33 G lancet
Description: Droplet personal lancet 33 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33 G lancet
Description: Droplet personal lancet 33 G
Study: NCT01529853

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SAR156597)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT00538629

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01107717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin\pioglitazone\exenatide
Description: metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
Study: NCT00222469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg IV on Day 1 Q 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 100mg/m2 on Day 2 and Q 2 weeks.
Study: NCT03436368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous spinal anesthesia
Description: Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
Study: NCT04334642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mindfulness based intervention
Description: It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
Study: NCT04223076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%, Corsodyl
Description: Comparison of Corsodyl and Curasept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%, Curasept
Description: Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
Study: NCT01929668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study: NCT01107717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin, glyburide and glargine
Description: subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
Study: NCT03479619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33 G lancet
Description: Droplet personal lancet 33 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33 G lancet
Description: Droplet personal lancet 33 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33 G lancet
Description: Droplet personal lancet 33 G

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33 G lancet
Description: Droplet personal lancet 33 G

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)
Study: NCT01118429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
Study: NCT03479619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)
Study: NCT04034875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: questionnaire
Study: NCT01696266

Intervention type: OTHER
Intervention: No treatment given
Description: Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
Study: NCT04642040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
Study: NCT02427425

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Study: NCT01118429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
Study: NCT01237704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation (TR)
Description: TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical stimulation (ES)
Description: Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
Study: NCT03644927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive exercise training
Description: The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
Study: NCT01503502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flumatinib
Description: Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flumatinib
Description: Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
Study: NCT03296397

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Gardasil
Description: Vaccination with Gardasil in patients apparently cured of external genital warts

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection of Normal Saline
Description: Injection of Normal Saline in patients apparently cured of external genital warts